Fasoracetam

Fasoracetam

Fasoracetam is a nootropic drug of the racetam family. It is a research chemical that was developed by the Japanese pharmaceutical company Nippon Shinyaku in the 1990s as a potential treatment for Alzheimer's disease.

History

Fasoracetam was first synthesized in the early 1990s by Nippon Shinyaku, a Japanese pharmaceutical company. The company initially developed the drug as a potential treatment for vascular dementia, but later shifted its focus to Alzheimer's disease. However, clinical trials were discontinued in 1995 due to lack of efficacy.

Pharmacology

Fasoracetam is a racetam compound, which means it shares a pyrrolidone nucleus with other drugs in this family, such as piracetam and aniracetam. It is believed to work by modulating glutamate, GABA, and acetylcholine neurotransmission. Specifically, fasoracetam has been shown to up-regulate GABA-B receptors and enhance cholinergic function.

Clinical Research

In recent years, fasoracetam has been the subject of renewed interest in the scientific community. A number of preclinical and clinical studies have been conducted to investigate its potential therapeutic effects. Some research suggests that fasoracetam may have nootropic effects, such as enhancing memory and cognition. Other studies have explored its potential as a treatment for conditions like ADHD and anxiety disorders.

Side Effects

As with any drug, fasoracetam can cause side effects. These may include headache, fatigue, nausea, and gastrointestinal discomfort. However, these side effects are generally mild and temporary. More research is needed to fully understand the safety profile of fasoracetam.

Legal Status

Fasoracetam is currently unregulated in many countries, including the United States. This means it can be purchased and used without a prescription. However, it is not approved by the Food and Drug Administration (FDA) for any medical use.

See Also

• Nootropics
• Racetam
• Nippon Shinyaku
• Alzheimer's disease
• ADHD
• Anxiety disorders